SGLT2 inhibitor series

SGLT2 inhibitorNot analyzed

C-glucoside SGLT2 inhibitors — empagliflozin, dapagliflozin, canagliflozin and sotagliflozin for glycemic and cardiorenal benefit.

Mechanism · SGLT2 inhibitor BioMoa · SGLT2 inhibitor BioMoa bridge · shared ID

No analysis recorded yet · 2 weeks cadence · refresh on /analyze · refresh recommended

Data sources: Catalog seed · PubChem · ChEMBL · ClinicalTrials.gov · FDA/EMA
Last updated: Not recorded
Similarity method: Morgan fingerprint, radius 2, 2048 bits, Tanimoto
Verified / known compounds: 4
Exploratory nodes: 1
Abstract scaffolds: 1
Relationship types: Derived (curated) · Fingerprint similarity · Drug-class link

StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.

Spider Web · Flow · Structure table · Compare · SMILES map

Name, 2D structure, SMILES, role, parent, core similarity, and traits. Click a row for details.

Compound	Role	SMILES	Parent	Core sim.	Traits
C-glucoside SGLT2 pharmacophoreAbstract pharmacophoresglt2-c-glucoside-corePage	Scaffold	`CCOC1=CC=C(C=C1)CC2=CC=C(C=C2)C3OC(CO)C(O)…`	—	—	SGLT2 · core · C-glucoside · Shared pharmacophore / core scaffold. Anchor for the SGLT2 inhibitor series lineage.
Canagliflozin (Invokana)Verified drugcanagliflozinPage	Drug	`CCOC1=CC=C(C=C1)CC2=CC(=CC(=C2)C3=CC=C(C=C…`	C-glucoside SGLT2 pharmacophore	—	SGLT2 · FDA · approved · T2D · Approved therapeutic. Canagliflozin (Invokana) in this family map.
Dapagliflozin (Farxiga)Verified drugdapagliflozinPage	Drug	`CCOC1=CC=C(C=C1)CC2=CC(=CC(=C2)C3=CC=C(C=C…`	C-glucoside SGLT2 pharmacophore	—	SGLT2 · FDA · approved · T2D · HF · Approved therapeutic. Dapagliflozin (Farxiga) in this family map. · CHEMBL184270 · CID 9887712
Empagliflozin (Jardiance)Verified drugempagliflozinPage	Drug	`CCOC1=CC=C(C=C1)CC2=CC(=CC(=C2)[C@@H](C3=C…`	C-glucoside SGLT2 pharmacophore	—	SGLT2 · FDA · approved · T2D · HF · Approved therapeutic. Empagliflozin (Jardiance) in this family map. · CHEMBL2107830 · CID 11949646
Sotagliflozin (Inpefa)Verified drugsotagliflozinPage	Drug	`CCOC1=CC=C(C=C1)CC2=CC(=CC(=C2)C3=CC=C(C=C…`	C-glucoside SGLT2 pharmacophore	—	SGLT2 · SGLT1 · FDA · approved · dual · Approved therapeutic. Sotagliflozin (Inpefa) in this family map.
Fluoro-aryl C-glucoside analogExploratory analog (rule-generated)sglt2-fluoro-aryl-analogPage	Derivative	`CCOC1=CC=C(C=C1)CC2=CC=C(C=C2)C3OC(CO)C(O)…`	C-glucoside SGLT2 pharmacophore	—	SAR · F-scan · SAR exploration node. Derived analog of parent node in SGLT2 inhibitor series.

From the core chemical, derivatives, drugs, and payloads fan out. Dashed orange chords are drug–drug links (spider web).

Loading map…

Clinical · regulatory context

SGLT2 — 당뇨·심부전·신장

C-glucoside 계열. 혈당 외 HF/CKD 적응증 확장이 핵심입니다.

Approved/clinical labels here come from the catalog clinical overlay. Agency names are shown when curated; live FDA/EMA APIs are not called.

EmpagliflozinApprovedFDA/EMA
T2D, HFrEF/HFpEF, CKD
ClinicalTrials.gov
DapagliflozinApprovedFDA/EMA
T2D, HF, CKD
ClinicalTrials.gov

Program and pipeline notes live on BioMoa · sglt2 · StructureMoa ↔ BioMoa bridge